CXJ-2

CXJ-2 is a cyclic peptide, and exhibits moderate affinity toward elastin derived peptides (EDPs) . CXJ-2 exhibits potent activities to inhibit the PI3K/ERK pathway and decrease hepatic stellate cell proliferation and migration. CXJ-2 possesses potent antifibrotic efficacy[1].

Product Specifications

CAS Number

[2919976-92-2]

UNSPSC

12352209

Target

ERK; PI3K

Type

Reference compound

Related Pathways

MAPK/ERK Pathway; PI3K/Akt/mTOR; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/cxj-2.html

Solubility

10 mM in DMSO

Smiles

O=C([C@@H](NC1=O)C(C)C)N[C@](CC)(C(NCC(N[C@H](C(N2[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N3[C@H](C(N[C@H]1C)=O)CCC3)=O)CO)=O)C)=O)CCC(O)=O)=O)CCC(O)=O)=O)CCC(N)=O)=O)C)=O)CO)=O)CCC2)=O)CO)=O)=O)C

Molecular Formula

C55H87N15O22

Molecular Weight

1310.37

References & Citations

[1]Song N, et al. Design and Discovery of Novel Cyclic Peptides as EDPs-EBP Interaction Inhibitors for the Treatment of Liver Fibrosis. J Med Chem. 2023 Apr 13;66 (7) :4689-4702.